Dr. Dinesh Khanna

👉University of Michigan Scleroderma Program leading the way through excellence in clinical care, teaching, & research #scleroderma tweets≠advice Follow≠endorse

[Dr. Dinesh Khanna @sclerodermaUM]

We've received very touching #sclerodermastories from patients & family. Read them all at the link below. Please consider supporting the Michigan Medicine Scleroderma Program on #GivingBlueday 11/27/18, at https://t.co/fdyuuD58PT … #medicineneedsvictors #victorsinthehouse #Rheum

[Dr. Dinesh Khanna @sclerodermaUM]

Exciting data on CAR-T from @Worldsclerofnd meeting in Athens in #scleroderma. Complete B cell depletion in tissue, response in RNA pol 3 Ab, and ++large clinical response. Clinical trials starting comparing CAR-T to standard of care therapies with Novartis and BMS.

[Dr. Dinesh Khanna @sclerodermaUM]

Join me and Dr Monalisa Ghosh to get an update on cell therapy in # scleroderma on Friday, December 12 - 2:00 p.m. ET. Sponosred by @scleroderma https://t.co/vnIMEVJkQU

[Dr. Dinesh Khanna @sclerodermaUM]

SLS 3 is published. https://t.co/gXyyHJLkp0
1. Upfront MMF+PFD vs. MMF+PLA
2. Underpowered due to Covid
3. No difference in primary end- FVC%
4. ⬆️AE and discont with MMF+PFD
What else did we learn?
A. Trends favor MMF+PFD in PROs and in HRCT QILD
B. Need well powered trials

[The Extracellular Matrix Pharmacology Congress @ecmcongress]

✨How can we better understand and treat fibrotic diseases?

Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM

He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

[Healio Rheumatology @HealioRheum]

📢 There were “clinical improvements in lung function and skin thickness in patients with severe refractory #SSc, with 96% remaining off SSc-directed therapies during the follow up,” said Dr. Dinesh Khanna @sclerodermaUM.

https://t.co/bhdPC5sRaf

[Dr. Dinesh Khanna @sclerodermaUM]

A lot of enthusiasm about CAR-T therapy in #scleroderma. Data from Phase 1 trial https://t.co/aBOaRF215N

[Dr. Dinesh Khanna @sclerodermaUM]

Proud moment. Neha Khanna, 2nd year undergraduate at UM presenting first author poster at #ACR25. Thanks to her mentor ⁦⁦@elizatsou⁩ and ⁦@UMIntMed⁩

[Healio Rheumatology @HealioRheum]

📢 “Preliminary meaningful improvement in #lung function and #skin thickness was observed” in patients with #SSc who received #CARTcelltherapy, said Dr. Dinesh Khanna @sclerodermaUM.

Read the full story from #ACR25 here 👇

https://t.co/bhdPC5sRaf

[Dr. Dinesh Khanna @sclerodermaUM]

#ACR2025. Exciting data on CAR-T in SSc.
Oct 26: Efficacy and Safety of BMS-986353, a CD19-Directed Chimeric Antigen Receptor T Cell Therapy: Phase 1 Trial in SSc
Oct 27: RESET-SSc: Clinical Trial Evaluating Rese-cel Autologous 4-1BB CD19-CAR T Cell Therapy in Phase 1 in SSc

[Med Learning Group @MLG_CME]

🫁Better understand key characteristics and diverse subtypes of fibrosing #interstitiallungdisease with our NEW CE #Webinar Series! Register Now: https://t.co/rqapDZNj7S

@sclerodermaUM

@DrBernstein
#Rheumatology #rheumatologists #InterstitialLungDisease #LungDisease #CME

[Dr. Dinesh Khanna @sclerodermaUM]

Interested in a career in scleroderma and related disorders? Join one of the largest programs with robust clinical research and trials. We are actively recruiting! @UMIntMed

https://t.co/lDtCfruoWr
📷

[Dr. Dinesh Khanna @sclerodermaUM]

Join me and @Kahlenberglab today at 11 am ET https://t.co/awIB9JPlOa Thanks to @Nordic_Bio for inviting us!

[Dr. Dinesh Khanna @sclerodermaUM]

Interested in a career in scleroderma and related disorders? Join one of the largest programs with robust clinical research and trials. We are actively recruiting! @UMIntMed

https://t.co/lDtCfruoWr
📷

[Dr. Dinesh Khanna @sclerodermaUM]

Interested in a position at U-M scleroderma program? Expertise in analyzing omics data. We are leading center in clinical trials and one of the largest scleroderma program.
https://t.co/hoMCUzTHcb

[U-M Department of Internal Medicine @UMIntMed]

Join us today at 12 pm for Grand Rounds on "Systemic Sclerosis: An Update" presented by @sclerodermaUM, professor in the Division of Rheumatology.

Learn more: https://t.co/H8svS3VM1m

[Dr. Dinesh Khanna @sclerodermaUM]

Delighted to present @UMIntMed grand rounds today at noon ET. Systemic Sclerosis- an update! Join at https://t.co/YndJldBcr8
Password:  606879

[Dr. John Cush @RheumNow]

DID YOU KNOW? >30% of Systemic Sclerosis pts present without Raynauds!. Data from 2 large US cohorts, of SSc dx with puffy fingers/hands or other symptoms. Such patients presented with more severe skin and musculoskeletal disease. https://t.co/NP3KeUL5iX

[Dr. Dinesh Khanna @sclerodermaUM]

Our first person Susan Chrysogelos who received CAR-T #scleroderma @UMIntMed @srfcure @scleroderma https://t.co/tyhjqogXaI #findcureforscleroderma

[MyRheumatology @rheumatologymy]

Bringing rheumatology closer to haematology. CAR-T therapy is showing tremendous promise in autoimmune conditions esp difficult to treat cases. #eular2025

[Dr. Dinesh Khanna @sclerodermaUM]

“Normal” CPK by race and gender. ⁦@docrota⁩ ⁦@FloridaRheums⁩